WHO recommends that Therapeutic Efficacy Studies (TES) for 1st and 2nd line antimalarial
medicines should be routinely carried out and data made available for decision-making due to
the threat of emergence and spread of artemisinin resistance in malaria-endemic countries,
especially in Africa. In line with this WHO recommendation, Rwanda Ministry of Health (MOH)
is conducting the TES to determine the efficacy of artemether-lumefantrine (ALN), which has
been used in Rwanda for the last 14 years) and dihydroartemisinin-piperaquine (DHA-PPQ),
another WHO-approved drug for the treatment of uncomplicated malaria which, though, has not
been used in Rwanda, is being considered for adoption as a second line or alternative first
line treatment. The objective of this study is to inform the decisions or actions made by a
public health authority (Rwanda Rwanda Ministry of Health) to inform decision on revision of
the antimalarial guidelines and policy in Rwanda. Jhpiego's Impact Malaria project in Rwanda,
with funding and technical oversight from US President's Malaria Initiative (PMI) through
USAID and CDC, will support the Rwanda MOH in its effort to evaluate the efficacy of ALN and
DHA-PPQ in the treatment of children with uncomplicated malaria. The study is being conducted
by Rwanda MOH, with technical support and funding by PMI-USAID through Jhpiego in Rwanda.
Phase:
Phase 4
Details
Lead Sponsor:
Jhpiego
Collaborators:
Centers for Disease Control and Prevention Ministry of Health, Rwanda United States Agency for International Development (USAID)
Treatments:
Artemether Artemether, Lumefantrine Drug Combination Artenimol Dihydroartemisinin Lumefantrine Piperaquine